HIF1A-AS2

Summary

HIF1A-AS2 (HIF1A antisense RNA 2, HGNC:43015) is a long non-coding RNA gene on chromosome 14q23.2.

At a glance

• Clinical variants (ClinVar): 1 total

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43015
Approved symbol	HIF1A-AS2
Name	HIF1A antisense RNA 2
Location	14q23.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	3’aHIF-1A, aHIF
OMIM	614529
Entrez	100750247
RNAcentral	URS000075BB37 — lncRNA, 2051 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EPAS1, HIF1A

Literature-anchored findings (GeneRIF, showing 13)

• Suggest that HIF1A-AS2 plays oncogenic roles and can be used as a therapeutic target for treating human bladder cancer using tetracycline-inducible shRNA . (PMID:27018306)
• HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches (PMID:27264189)
• HIF1A-AS2 contributes to glioblastoma multiforme stem-like cells’ speciation and adaptation to hypoxia within the tumor microenvironment. (PMID:27264189)
• significantly increased in plasma of patients with triple-negative breast cancer (PMID:28248879)
• HIF1A-AS2 exerted the oncogenic functions in CRC through regulating miR-129-5p/DNMT3A axis. (PMID:29278853)
• This study suggests that upregulated HIF1A-AS2 hampers the p53 family proteins dependent apoptotic pathway to promote Cisplatin resistance in bladder cancer. These results suggested that HIF1A-AS2 plays oncogenic roles and can be used as a therapeutic target for treating human bladder cancer. (PMID:30216500)
• Results identified AHIF was significantly upregulated in glioblastoma multiforme (GBM) tissues, as well as in radioresistant GBM cells. Also, the study establishes that AHIF promotes GBM progression and radioresistance via exosomes. (PMID:30387845)
• High expression of HIF1A-AS2 was associated with lymph node metastasis, distant metastasis and unfavorable histological grade in the triple-negative breast cancer patients.HIF1A-AS2 high expression acted as an independent poor prognostic factor for overall survival in the triple-negative breast cancer patients. (PMID:30635931)
• KCNQ1OT1, HIF1A-AS2 and APOA1-AS are promising novel biomarkers for diagnosis of coronary artery disease (PMID:30941792)
• LncRNA HIF1A-AS2 promotes osteosarcoma progression by acting as a sponge of miR-129-5p. (PMID:31866584)
• Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy. (PMID:34378101)
• The evolving role of long noncoding RNA HIF1A-AS2 in diabetic retinopathy: a cross-link axis between hypoxia, oxidative stress and angiogenesis via MAPK/VEGF-dependent pathway. (PMID:35285425)
• LncRNA HIF1A-AS2 modulated by HPV16 E6 regulates apoptosis of cervical cancer cells via P53/caspase9/caspase3 axis. (PMID:35728704)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000192678 (14:61748985 A>C), RS1000351887 (14:61747656 C>A,T), RS1000798130 (14:61750209 T>G), RS1001681022 (14:61748740 T>C), RS1002016670 (14:61747018 C>G), RS1002798872 (14:61749994 G>A,T), RS1003250403 (14:61748095 T>A,C), RS1003254454 (14:61748434 AAAT>A), RS1004316145 (14:61750280 A>G), RS1004527621 (14:61749233 T>A,C), RS1004605714 (14:61750659 A>C,T), RS1005045505 (14:61748849 T>C), RS1006286846 (14:61749534 C>T), RS1007341362 (14:61750514 T>C), RS1008558586 (14:61747446 C>G,T)

Disease associations

OMIM: gene MIM:614529 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 0 entries

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
bisphenol F	decreases expression	1
bisphenol S	decreases expression	1
jinfukang	decreases expression	1
Cisplatin	decreases expression	1
Estradiol	increases expression	1
Lactic Acid	increases expression	1
Particulate Matter	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.